Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune ...

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819...

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune ...

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy - Fate Therapeutics (NASDAQ:FATE)

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning

Fate (NASDAQ: FATE) posts FT819 SLE data: 10 treated, no DLTs; CRR at 6 months

Phase 1 FT819 in SLE: all >3‑month patients (n=5) showed SLEDAI‑2K and PGA declines; two LN patients achieved CRR at 6 months. No ICANS/GvHD; no DLTs.